Exploiting a purine imbalance to target KRAS mutant pancreatic adenocarcinomas. Mota-Pino J, Fernandez-Capetillo O. Gut 2026 Feb 4:gutjnl-2025-337940. doi: 10.1136/gutjnl-2025-337940.

Read + Share

Amedeo Smart

Independent Medical Education

Mota-Pino J, Fernandez-Capetillo O. Exploiting a purine imbalance to target KRAS mutant pancreatic adenocarcinomas. Gut 2026 Feb 4:gutjnl-2025-337940. doi: 10.1136/gutjnl-2025-337940.
PMID: 41638888